A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC).

Trial Profile

A Randomized Phase II Study of Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy for Advance Non-small Cell Lung Cancer(NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2015

At a glance

  • Drugs Imetelstat (Primary) ; Bevacizumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Geron Corporation
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 05 Apr 2013 Data, including a subgroup analysis, will be presented at the American Association for Cancer Research Annual Meeting 2013, according to a Sarah Cannon Research Institute media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top